StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen MVASI (bevacizumab-awwb by Quarter

MVASI (bevacizumab-awwb — Avastin Oncology Biosimilar) — U.S. product sales ($M) ($M)

QuarterlyAnnual

Amgen MVASI (bevacizumab-awwb: $106M in Q2 2026, down 25.4% from a year earlier.

Latest, Q2 2026
106
Period ended Jun 30, 2026
Change on a year earlier
-25.4%
142 in Q2 2025
History
28 quarters
Since Q3 2019
Sources
28
Documents cited below

Where the Q2 2026 figure comes from

“|| MVASI ® | 106 | 47 | 153 | 191 | (20%)”

Source: Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedMVASI (bevacizumab-awwb — Avastin Oncology Biosimilar) — U.S. product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026106-25.4%Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 202696-30.4%Form 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗
Q4 2025Dec 31, 2025137+26.9%Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 2025156+14.7%Form 8-K (amgn-20250930earningsrelea.htm, filed 2025-11-04) ↗
Q2 2025Jun 30, 2025142+42.0%Form 8-K (amgn-20250630earningsrelea.htm, filed 2025-08-05) ↗
Q1 2025Mar 31, 2025138+31.4%Form 8-K (amgn-20250331earningsrelea.htm, filed 2025-05-01) ↗
Q4 2024Dec 31, 2024108-15.0%Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 2024136-2.9%Form 8-K (amgn-20240930earningsrelea.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 2024100-18.7%Form 8-K (amgn-20240630earningsrelea.htm, filed 2024-08-06) ↗
Q1 2024Mar 31, 2024105-13.2%Form 8-K (amgn-20240331earningsrelea.htm, filed 2024-05-02) ↗
Q4 2023Dec 31, 2023127-5.2%Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
Q3 2023Sep 30, 2023140+0.7%Form 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗
Q2 2023Jun 30, 2023123-23.6%Form 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗
Q1 2023Mar 31, 2023121-28.0%Form 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 2022134-35.9%Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Q3 2022Sep 30, 2022139-25.7%Form 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗

Cite this data

StockData. (2026). Amgen MVASI (bevacizumab-awwb ($M), quarterly Q3 2019–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-mvasi-us

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.